CHARACTERISTICS OF THE SCINTIGRAPHY WITH 99mTc- PERTECHNETATE IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA
Abstract
Introduction: Differentiated thyroid carcinoma (DTC) derived from follicular cells is the most frequent endocrine malignancy, which most commonly occurs in patients with thyroid nodules.
Aim: The aim of this retrospective analysis is to examine the type of scintigraphic finding of the thyroid gland obtained with 99mTc-pertechnetate in patients with DTC before tireoidectomy.
Material and methods: Medical documentation comprised of 95 subjects with presurgical evaluation of thyroid nodules, including 18 men (51.5 ± 8.7 years old, range 43-68) and 77 women (48 ± 12, range 14-72 years). Other tests performed during the preoperative tests are the following: ultrasound examination of the thyroid gland, thyrotropin and thyroglobulin concentration measurement.
Results: During the preoperative evaluation, thyroid ultrasound was performed in 20 (21%) out of 95 subjects with DTC, while 99mTc-pertechnetate scintigraphy was performed in 75 (79%) of patients, in addition to a clinical examination. What is the distribution of scintigraphic finding? Significantly, the highest incidence of DTC was found in the multinodular goiter: 61 (64%) subjects were diagnosed with this type of DTC, while 31 (33%) carcinomas were found in abnormal, solitary ”cold” nodules. The most frequent histopathological finding amongst nodules and multinodular goiter detected by scintigraphy was papillary thyroid carcinoma. Thyroid carcinoma was found in two patients with Graves’ disease and in one patient with a normal scintigraphic finding. The values of thyroid hormones were normal in 71% of DTC and elevated in fewer cases (21%). The ultrasound examination showed high-risk features in only 18 subjects (19%).
Conclusion: Our results have shown that DTC is the most common finding in the multinodal goiter, and that it occurs much less often within the “cold” thyroid nodules. In a small percentage of subjects, thyroid neoplasm was found in patients with hyperthyroidism. The results of the study showed that thyroid gland scintigraphy with 99mTc-pertechnetate still has a significant diagnostic role in the examination of thyroid nodules.
References
Yeung MJ, Serpell JW. Management of the Solitary Thyroid Nodule. The Oncologist 2008;13:105–112.
Jossart GH, Clark OH. Well-differentiated thyroid cancer. Curr Prob Surg 1994; 31:935–1011.
Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993; 328:553–559.
Tuttle RM, Lemar H, Burch HB. Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration. Thyroid 1998; 8: 377-383.
Kumar H, Daykin J, Holder R, Watkinson JC, Sheppard M, Franklyn JA. Gender, clinical findings and serum thyrotropin measurements in the prediction of thyroid neoplasia in 1005 patients presenting with thyroid enlargement and investigated by fine-needle aspiration cytology. Thyroid 1999; 11:1105-1109.
Bennedbaek FN, Perrild H, Hegedüs L. Diagnosis and treatment of the solitary thyroid nodule. Results of a European survey. Clin Endocrinol 1999;50(3):357-363.
Meller J, Becker W. The continuing importance of thyroid scintigraphy in the era of high-resolution ultrasound.Eur J Nucl Med 2002; 29 (Suppl. 2):425–438.
Royaux IE, Wall SM, Karniski LP, Everett LA, Suzuki K, Knepper MA, Green ED. Pendrin, encoded by the Pendred syndrome gene, resides in the apical region of renal intercalated cells and mediates bicarbonate secretion. Proc Natl Acad Sci U S A2001;98:4221–4226.
Shimmins J, Alexander WD, McLarty DG, Robertson JWK, Sloane D. 99mTc-pertechnetate for measuring thyroid suppressibility. J Nucl Med 1971; 12:51–54.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodulesand Differentiated Thyroid Cancer. Thyroid 2016; 26(1): 1–133.
Raber W, Kaserer K, Niederle B, Vierhapper H. Risk factors formalignancy of thyroid nodules initially identified as follicularneoplasia by fine-needle aspiration: results of a prospective studyof one hundred twenty patients. Thyroid 2000; 10:709–712.
Mackenzie EJ, Mortimer RH. 6: thyroid nodules and thyroid cancer. Med J Aust2004;180(5):242–247.
Wale A,Miles KA, Young B, Zammit C, Williams A, Quin J, Dizdarevic S. Combined 99mTc-methoxyisobutylisonitrile scintigraphy and fine-needle aspiration cytology offers an accurate and potentially cost-effective investigative strategy for the assessment of solitary or dominant thyroid nodules. Eur J Nucl Med Mol Imaging 2014; 41:105–115.
Paul SJ, Sisson JC. Thyrotoxicosis caused by thyro-id cancer. Endocrinol Metab Clin North Am 1990;19(3):593-612.
David E, Rosen IB, Bain J, James J, Kirsh JC. Management of the hot thyroid nodule. Am J Surg 1995;170(5):481-83.
Gabriele R, Letizia C, Borghese M, De Toma G, Celi M, et al. Thyroid cancer in patients with hyperthyroidism. Horm Res 2003;60:79-83.
Chigot JP, Ménégaux F, Keopadabsy K, Hoang C, Aurengo A, Leenhardt L, et al. Thyroid can-cer in patients with hyperthyroidism. Presse Med 2000;29(36):1969-72.
Als C, Gedeon P, Rösler H, Minder C, Netzer P, Laissue JA. Survival analysis of 19 patients with toxic thyroid carcinoma. J Clin Endocrinol Metab 2002;87(9):4122-27.
Iranmanesh P, Pusztaszeri M, Robert J, Meyer P, Schiltz B, Sadowski SM, et al.Thyroid Carcinoma in Hot Nodules: Review of the Literature.World Journal of Endocrine Surgery 2013;5(2):50-54.
Pellegriti G, Mannarino C, Russo M, Terranova R, Marturano I, Vigneri R, et al. Increased mortality in patients with differentiated thyroid cancer associated with Graves’ disease. J Clin Endocrinol Metab 2013;98:1014-1021.
Boostrom S, Richards ML. Total thyroidectomy is the preferred treatment for patients with Graves’ disease and a thyroid nodule. Otolaryngol Head Neck Surg 2007;136:278-281.
Belfiore A, Russo D, Vigneri R, Filetti S. Graves’ disease, thyroid nodules and thyroid cancer. Clin Endocrinol 2001;55:711-718.
Pazaitou-Panayiotou K, Michalakis K, Paschke R. Thyroid cancer in patients with hyperthyroidism. Horm Metab Res 2012;44:255-262.